Dogwood Therapeutics names OrbiMed’s Iain Dukes chair of new scientific advisory board

Dogwood Therapeutics Inc

Dogwood Therapeutics Inc

DWTX

0.00
  • Dogwood Therapeutics named OrbiMed venture partner Iain Dukes chair of its newly formed Scientific Advisory Board.
  • Dukes will advise leadership on scientific strategy for pain and neuropathy programs, including Halneuron in chemotherapy-induced neuropathic pain.
  • He previously led business development and licensing at Merck Research Laboratories, following external R&D leadership roles at Amgen and GlaxoSmithKline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300845PRIMZONEFULLFEED9754295) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.